Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 8/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | EPOR | P19235 | 1/20 | 0.31 |
| ▸ | TACR2 | P21452 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13839054 | 0.87 | TLR2 (0.40) | TLR2SIRT6SIRT1MEN1KMT2A | |
| SCHEMBL12196382 | 0.76 | MEN1 (0.38) | TLR2SIRT6SIRT1MEN1KMT2A | |
| SCHEMBL12706048 | 0.75 | MEN1 (0.38) | TLR2SIRT6SIRT1MEN1KMT2A | |
| SCHEMBL13839052 | 0.72 | SIRT6 (0.44) | TLR2SIRT6SIRT1MEN1KMT2A | |
| SCHEMBL12196488 | 0.71 | TLR2 (0.43) | TLR2SIRT6SIRT1MEN1KMT2A | |
| SCHEMBL12706033 | 0.70 | MEN1 (0.34) | TLR2MEN1KMT2ACA2EPOR | |
| SCHEMBL14586327 | 0.68 | TLR2 (0.45) | TLR2SIRT6SIRT1MEN1KMT2A | |
| SCHEMBL14078185 | 0.68 | TLR2 (0.45) | TLR2SIRT6SIRT1MEN1KMT2A | |
| SCHEMBL12196495 | 0.67 | TLR2 (0.40) | TLR2SIRT6SIRT1MEN1KMT2A | |
| SCHEMBL16830731 | 0.66 | GLP1R (0.41) | TLR2SIRT6SIRT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729030-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130079283-A1 | Erythropoitein Receptor Peptide Formulations and Uses | AFFYMAX, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8324159-B2 | Erythropoietin receptor peptide formulations and uses | AFFYMAX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110245176-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-7855175-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090118183-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | AFFYMAX, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090048166-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20070032408-A1 | Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118183-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | EPOR, PROKR1, PROKR2 | TLR2 1494/4885SIRT6 2462/4885SIRT1 3110/4885 |
| US-20090048166-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | TLR2 2680/4885SIRT6 3745/4885SIRT1 4168/4885 |
| US-20110245176-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | TLR2 2680/4885SIRT6 3745/4885SIRT1 4168/4885 |
| US-20130079283-A1 | Erythropoitein Receptor Peptide Formulations and Uses | EPOR, MPL, PROKR1 | TLR2 1704/4885SIRT6 2732/4885SIRT1 3382/4885 |
| US-20070032408-A1 | Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds | NGLY1, YWHAZ, PAM | TLR2 1126/4885SIRT6 4806/4885SIRT1 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.